Division of Strategic Planning and Evaluation Research Projects on COVID-19

Rapid research and development (R&D) is now required to address the novel coronavirus disease (COVID-19) that has spread worldwide since its first outbreak reported in the People’s Republic of China in December 2019. In view of this urgent public health need, AMED is supporting R&D projects in the areas described below as part of a government-wide initiative.

(1) Diagnosis

Research Period Principal Investigator Affiliation Project Title General Description
FY2019 SUZUKI Tadaki Director, Department of Pathology, National Institute of Infectious Diseases Research on development of diagnostic tests for the novel coronavirus disease (COVID-19) The research group will aim to develop the basic technology for use in rapid diagnostic test kits for SARS-CoV-2. The group will focus on molecular and antibody based diagnostic technologies such as RT-LAMP, SARS-CoV-2 antigen detection assay, and anti-viral antibody detection assay. The group will also conduct viral genome analysis using clinical samples to develop robust diagnostic tests for SARS-CoV-2.
FY2020 ISOBE
Masaharu
Professor,
Faculty of Engineering ,
University of Toyama
Research on the development of immediate clinical testing systems for SARS-CoV-2 To Be Announced
FY2020 UZAWA
Takanori
Senior research scientist,
RIKEN Cluster for Pioneering Research  Nano Medical Engineering laboratory,
RIKEN
Development of BEF peptides for visualization virus in live cell To Be Announced
FY2020 MARUYAMA
Atsushi
Professor,
School of Life Science and Technology ,
Tokyo Institute of Technology
Highly customizable, rapid and simple detection of pathogen-related RNA To Be Announced
FY2020 YOSHIMI
Kazuto
Senior Assistant Professor ,
The Institute of Medical Science,
The University of Tokyo
Precision and portable diagnostics for viruses with new genome editing technology To Be Announced

(2) Therapeutics

Research Period Principal Investigator Affiliation Project Title General Description
FY2019 TAKEDA Makoto Director, Department of Virology 3, National Institute of Infectious Diseases Research on  replication mechanisms and anti-viral therapeutic agents of the novel coronavirus

To develop therapeutic drugs for the novel betacoronavirus, SARS-CoV-2, multiple approaches are being used to identify compounds that inhibit the virus growth. By random screening of existing approved drug libraries and other compound libraries and infection mechanism, structural and biological evidence-based drug screening, infection-inhibitory molecules that suppress viral infection can be identified. In addition, by using a high-throughput monoclonal antibody isolation technique, a human type therapeutic monoclonal antibody against the virus is rapidly being established. 

Currently work is being done on the analysis of infection mechanisms, purification and structural analysis of high-purity proteins, screening of small molecule compound libraries, preparation of recombinant antigens targeting therapeutic antibodies, research and development of human monoclonal antibodies using these antigens, screening of existing drugs, virus propagation development of a real-time RT-PCR system for monitoring systems and screening of natural compound libraries.

Research participants: National Institute of Infectious Diseases, Hokkaido University, Kitasato University, Kyushu University

FY2020 YONEMITSU
Yoshikazu
Professor,
Graduate School of Pharmaceutical Sciences,
Kyushu University
Development of therapeutic vaccine-like cell-based drug available to various emerging infectious
diseases
To Be Announced
FY2020 OKUNO
Takayuki
Project manager,
Research Planning Development ,
Shionogi & Co., Ltd.
Therapeutic small molecule drug development program for novel coronavirus disease (COVID-19) To Be Announced
FY2020 KITANO
Mitsuaki
Head of Basic Research Group ,
Pharma & Supplemental Nutrition Solutions Vehicle ,
KANEKA CORPORATION
Development program for therapeutic neutralizing antibodies against the Novel Coronavirus (SARS-CoV-2) To Be Announced
FY2020 OKAMURA
Kentaro
Director ,
Department of Manufacturing Technology ,
Human Life CORD Inc
Phase 1 Clinical Trial Using Allogenic Umbilical Cord-derived Mesenchymal Stromal Cells in Severe
COVID-19-related ARDS
To Be Announced
FY2020 SHIMASAKI
Shigeki
COO & Head of R&D,
Research & Development,
Nobelpharma Co Ltd.
Conducting Phase II/III study of rhGM-CSF in patients with novel coronavirus infection (COVID-19). To Be Announced
FY2020 TSUKAHARA
Kappei
Chief Data Officer,
Tsukuba Research Laboratories,
Eisai Co.,Ltd.
Development of therapeutic drugs for preventing the progression to severe COVID-19 To Be Announced
FY2020 SHINDO
Yuichiro
Assistant Professor ,
Department of Respiratory Medicine ,
Nagoya University
Japanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease (COVID-19) patients with mild respiratory failure: J-CRITICAL trial To Be Announced
FY2020 MITSUYA
Hiroaki
Director General ,
Research Institute,
National Center for Global Health and Medicine
Developing main protease inhibitor for COVID-19 treatment To Be Announced
FY2020

HANAKI
Hideaki

 

Director,
Ōmura Satoshi Memorial Institute ,
Kitasato University
Development of COVID-19 therapeutic agent based on the Ōmura natural compound, Avermectin To Be Announced
FY2020 YAMAOKA
Kunihiro
Professor,
Department of Rheumatology and Infectious Diseases,
Kitasato University
COVID-19 Kitasato Project; Investigator-initiated clinical trial of ivermectin for additional indication to COVID-19 To Be Announced
FY2020 MAEDA
Kenji
National Center for Global Health and Medicine Establishing convalescent plasma treatment for COVID-19 To Be Announced
FY2020 TSUSHIMA
Kenji
Section Chief ,
Dep. of Refractory Viral Infection, Research Institute ,
International University of Health and Welfare, 
School of Medicine
Treatment strategy with combination therapy for novel coronavirus disease (COVID-19) To Be Announced
FY2020 ISHIZAKA
Yukihito
Director,
Department of Intractable Diseases,
National Center for Global Healthand Medicine
Developing COVD-19 specific globulin agents by identifying epitopes of neutralizing antibodies in convalescent
patients. 
To Be Announced
FY2020 OKAMOTO
Toru
Professor,
Research Institute for Microbial Diseases,
Osaka University
Development and safety assessment of combination drugs and nucleolus-related novel drugs for COVID-19 To Be Announced
FY2020 YASUTOMO
Koji
Professor,
Immunology, Graduate School of Medicine,
Tokushima University
Development of a therapeutic antibody cocktail for COVID-19 To Be Announced
FY2020 HONJO
Tasuku
Professor,
Department of Immunology and Genomic Medicine,
Kyoto University
Immunoregulatory drug development to prevent recurrent pandemic COVID-19 To Be Announced
FY2020 HARIGAE
Hideo
Professor,
Graduate School of Medicine,
Tohoku Universi
A phase II investigator-initiated study to evaluate the efficacy and safety of PAI-1 inhibitor TM5614
in patients with SARS-CoV-2 pneumonia
To Be Announced
FY2020 KAMITANI
Wataru
Professor,
Department of Infectious Diseases and Host Defense,
Gunma University
Development of anti-COVID-19 therapy to suppress severe pneumonia by combination using adenovirus vector
with ultra-multi guide RNA expression system and protease inhibitors.
To Be Announced
FY2020 TAKAORI
Akifumi
Professor,
Department of Hematology & Oncology ,
Kyoto University
Development of novel immunotherapy against COVID-19 using alpaca VHH technology To Be Announced
FY2020 KAWAMOTO
Hiroshi
Professor,
Institute for Frontier Life and Medical Sciences,
Kyoto University
Development of universal T cell therapy for novel coronavirus disease (COVID-19) To Be Announced
FY2020 HAGIWARA
Masatoshi
Professor,
Department of Anatomy and Developmental Biology,
Kyoto University
Therapeutic drug development program to suppress pandemic infection of COVID-19. To Be Announced
FY2020 MATSUSHITA
Shuzo
Professor,
Joint research Center for Human retrovirus Infection,
Kumamoto University
Establishment of human monoclonal antibodies that neutralize a novel coronavirus (SARS-CoV-2) To Be Announced
FY2020 KAWAOKA
Yoshihiro
Professor ,
Institute of Medical Science ,
University of Tokyo
Establishment of the antibody therapy against novel coronavirus disease (COVID-19) To Be Announced
FY2020 BABA
Masanori
Director,
Joint Research Center for Huma Retrovirus Infection ,
Kagoshima University
Development of novel amodiaquine derivatives effective in the treatment of novel coronavirus infection To Be Announced
FY2020 MASUTOMI
Kenkichi
 
Chief,
Division of Cancer Stem Cell,
National Cancer Center
Novel anti-viral strategy against SARS-CoV-2 by RdRP inhibitors To Be Announced
FY2020 KITAMURA
Kazuo
Professor ,
Department of Internal Medicine,
Miyazaki University
Therapeutic drug development for severe pneumonia requiring mechanical ventilation caused by
COVID-19 – Phase 2a trial
To Be Announced
FY2020 SAWAMURA
Tatsuya
Professor,
School of Medicine,
Shinshu University
Development of drug for the therapy of severe COVID-19 To Be Announced
FY2020 ODAGUCHI
Hiroshi
Director General,
Oriental Medicine Research Center ,
Kitasato
University
Development of a novel crude drug extract preparation which prevents the exacerbation of
COVID-19 patients in the early stage of infection
To Be Announced
FY2020 TAKEBE
Takanori
Professor,
Institute of Research,
Tokyo Medical and Dental University
 
Intestinal ventilation-based therapeutics development for COVID-19 related severe
respiratory complications
To Be Announced
FY2020 MATSUOKA
Sahoko
Director,
Department of safety research on blood and biologics,
National institute of infectious diseases
Development of new antiviral drugs against emerging and re-emerging infectious diseases, includingnovel coronavirus disease (COVID-19) To Be Announced
FY2020 YOKOTA
Koichi
General Manager / Executive Officer,
Department of Pharmacological Research ,
StemRIM Inc.
Development of in vivo tissue regeneration-inducing medicine for patients with COVID-19 pneumonia To Be Announced
FY2020 SHINJO
Hiroshi
CEO,Himuka AM Pharma Corp. Development of therapeutic drug for COVID-19 associated severe pneumonia. To Be Announced
FY2020 MATSUO
Takeru
Chief Researcher,
R&D Department,
SENTAN Pharma Inc.
Development of a novel COVID-19 therapeutic drug for asymptomatic and mild patients by using inhaled Development of a novel COVID-19 therapeutic drug for asymptomatic and mild patients by using inhaled To Be Announced
FY2020 NIO
Yasunori
Associate Director,
T-CiRA Discovery,
Takeda pharmaceutical company limited.
Development of novel complement targeting antibody therapy against fatal COVID-19 complications. To Be Announced
FY2020 NAGASE
Tsuyoshi
Head,Medicinal Chemistry Research Laboratories, Department of New Drug Research Division,
Otsuka Pharmaceutical Co., Ltd. 
Therapeutic drug development program based on targeted protein degradation for novel coronavirus
disease (COVID-19)
To Be Announced
FY2020 MAITA
Ayako
Researcher, Research and Development Department,
Curreio Inc.
Development of COVID-19 treatment based on the Cryo-EM Single Particle structur alanalysis of SARS-CoV-2 Target-DNA Aptamer complex To Be Announced
FY2020 TUCHIYA
Masayuki
Director,
Drug discovery and development department,
Epsilon Molecular Engineering Inc.
Development of multivalent VHH antibody drug for novel coronavirus infection (COVID-19) To Be Announced
FY2020 KUROSAWA
Tooru
Executive Officer, Associate General Manager, Pharmaceutical R&D Division ,Meiji Seika Pharma Co., Ltd. Therapeutic antibody development program for novel coronavirus disease (COVID-19) To Be Announced
FY2020 NAGABUKURO
Hiroshi
Chief executive officer,
ARTham Therapeutics Inc.
Development of novel pharmacotherapy to prevent development of severe conditions in patients with COVID-19 and to improve long-term prognosis, and its companion diagnostics To Be Announced
FY2020 FUJITA
Yu
Assistant Professor ,
Division of Respiratory Medicine, Department of Internal Medicine,
The Jikei University School of Medicine
 
Development and product utilization of innovative inhaled exosome medicine for COVID-19-induced severe pneumonia and ARDS To Be Announced
FY2020 MATSUURA
Yoshiharu
Professor ,
Research Institute for Microbial Diseases,
Osaka University
Mechanism-based research for discovery of anti-SARS2-CoV-2 drugs To Be Announced
FY2020 TAKESHITA
Masaru
Project Assistant Professor,
School of Medicine ,
Keio University
Therapeutic drug development of neutralizing antibody against novel coronavirus (SARS-CoV-2) To Be Announced
FY2020 MINAKAWA
Noriaki
Professor ,Faculty of Pharmaceutical Sciences, Tokushima University Development of nucleoside antimetabolites toward emerging / reemerging infectious diseases including novel coronavirus disease (COVID-19) To Be Announced
FY2020 KINJO
Takeshi
Assistant Professor ,
Department of Respiratory diseases and infection,
University of the Ryukyus
Development of anti-inflammatory treatment with low dose colchicine for prevention of host
inflammatory response phase in patients with novel coronavirus disease (COVID-19) through a physician-initiated clinical trial
To Be Announced
FY2020 AOYAGI
Tetsuji
Associate Professor ,
Internal Medicine, Department of Infectious Diseases ,
Tohoku University
A phase II clinical trial with HLH-94 protocol, etoposide plus corticosteroid combination therapy, for
severe illness patients with COVID-19
To Be Announced
FY2020 WADA
Takehiko
Professor,
Institute of Multidisciplinary Research for Advanced
Materials Professor,
Tohoku University

 
Creation of infectious disease treatment platform by novel nucleic acid therapeutics with remarkably
enhanced catalytic target RNA cleavage activities
To Be Announced
FY2020 OHMAGARI
Norio
Director,
Disease Control and Prevention Centre,
Centre Hospital of the National Center for Global Health
Research and development for establishment of the treatment for COVID-19 To Be Announced
FY2020 MAENAKA
Katsumi
Professor,
Faculty of Pharmaceutical Sciences,
Hokkaido University
Therapeutic antibody development for novel coronavirus disease (COVID-19) based on deep
structural analysis
To Be Announced
FY2020 OBIKA
Satoshi
Professor,
Graduate School of Pharmaceutical Sciences,
Osaka University
 
Development of antisense oligonucleotides for the treatment of novel coronavirus disease and establishment
of methods for the prediction and evaluation of off-target toxicity
To Be Announced
FY2020 OHOKA
Nobumichi
 
Section Chief,
Division of Molecular Target and Gene Therapy Products,
National Institute of Health Sciences
Development of proteolysis-inducing drugs for COVID-19 and establishment of the off-target evaluation method. To Be Announced
FY2020 IWATANI
Yasumasa
Department Chief,
Clinical Research Center,
National Hospital Organization Nagoya Medical Center
Therapeutic drug development utilizing antibody mimetics against SARS-CoV-2 To Be Announced
FY2020 HOSHINO
Atsushi
Assistant Professor,
Department of Cardiovascular medicine,
Kyoto Prefectural University of Medicine
Resistance-free SARS-CoV-2 neutralizing drug development with high-affinity modified ACE2
protein.
To Be Announced
FY2020 KIDOYA
Hiroyasu
Associate Professor,
Research Institute for Microbial Diseases,
Osaka University
Development of vasoprotective drug for improving the effect of antiviral drug against COVID-19 To Be Announced
FY2020 SAITO
Yoshiro
Director,
Division of Medicinal Safety Science,
National Institute of Health Sciences
Biomarker exploration on novel coronavirus infectious disease (COVID-19) pneumonia for proper treatment To Be Announced
FY2020 YAMAHARA
Kenichi
Associate Professor,
School of Medicine,
Hyogo College of Medicine
Optimization of amniotic mesenchymal stem cell therapy to treat cytokine storms by COVID-19 To Be Announced

(3) Vaccine

Research Period Principal Investigator Affiliation Project Title General Description
FY2019 HASEGAWA Hideki Director, Influenza Virus Research Center, National Institute of Infectious Diseases Research on development of vaccines of the novel coronavirus disease(COVID-19) The research group will aim to develop a new vaccine by combining adjuvant and antigen vaccine using recombinant protein synthesis.
FY2019 KAWAOKA Yoshihiro Professor, Institute of Medical Science, The University of Tokyo Study on the control of a novel coronavirus (2019-nCoV) This research aims to develop effective therapeutics and vaccines against SARS-CoV-2 by undertaking the following:
1) establish an animal model for the SARS-CoV-2 infection. We will determine whether marmosets, hamsters, mice, or ferrets that are susceptible to SARS-CoV or MERS-CoV are useful as animal models of SARS-CoV-2 infection.
2) establish human monoclonal antibodies to SARS-CoV-2 from peripheral blood mononuclear cells of SARS-CoV-2-infected patients and verify their usefulness as therapeutic antibodies in animal models.
3) generate an mRNA vaccine encoding the spike(S) protein, a coronavirus infection protection antigen, and verify the protective effects of this vaccine in animal models. The basic technology for mRNA vaccines has already been established by the Japanese company Daiichi Sankyo Co. Ltd. Even with limited information about SARS-CoV-2 growth mechanisms, it is feasible to develop mRNA vaccines, which are relatively easy to design and do not require cell substrates for vaccine production.
FY2020 ITOH
Yasushi
Professor,
Department of Pathology,
Shiga University of Medical Science
Development of a recombinant vaccine against SARS-CoV-2 using a cynomolgus macaque model To Be Announced
FY2020 TANAKA
Yoshimasa
Professor ,
Center for Medical Innovation ,
Nagasaki University
Development of vaccines against COVID-19 To Be Announced
FY2020 MORITA
Eiji
Associate Professor,
Department of Biochemistry and Molecular Biology,
Hirosaki University
Development of SARS-CoV-2 nanoparticle vaccine inducing mucosal immune responses To Be Announced
FY2020 WATANABE
Yoshihiro
Professor,
Innovative Clinical Research, Center of Hospital
Kanazawa University
Development of sublingual vaccine to induce the defined epitope-specific IgA able to protect
infection of the novel corona virus.
To Be Announced

Reference

DAIICHI SANKYO COMPANY, LIMITED Website:
Our Company's Efforts to Limit the Spread of the Virus that Causes COVID-19

(4) Clinical Research

Research Period Principal Investigator Affiliation Project Title General Description
FY2019 YUZAWA Yukio Hospital Director, Fujita Health University Hospital Study on multicenter open-label randomized clinical trial of favipiravir to evaluate the viral load reduction effect in asymptomatic and mild patients with SARS-CoV2 infection/A multicenter observational study to evaluate the clinical course of moderate and severe patients receiving favipiravir Favipiravir is an antiviral drug created by Toyama Chemical Co., Ltd. (Fujifilm Toyama Chemical Co., Ltd.) It was approved by the Ministry of Health, Labor and Welfare in March 2014, limiting the indications and effects to “emerging or re-emerging influenza virus infections (only if other anti-influenza virus drugs are ineffective or insufficiently effective).” The mechanism of action is that triphosphorylated form (T-705RTP) converted in vivo selectively inhibits viral RNA polymerase, so it is expected to be effective against RNA viruses other than influenza virus, but there is no evidence of utility for SARS-CoV2 infection.
The aim of this research is to clarify the usefulness of favipiravir for asymptomatic and mild patients with SARS-CoV2 infection and the clinical course of moderate and severe patients receiving favipiravir by Specified Clinical Research.

(5) Scientific Research on COVID-19

Research Period Principal Investigator Affiliation Project Title General Description
FY2020 SATO
Kei
Associate Professor (Principal Investigator),
Institute of Medical Science ,
University of Tokyo
Investigation of the biological principle of the pathogenicity and cross-species transmission of
emerging virus infections including SARS-CoV-2
To Be Announced
FY2020 SUGIYAMA
Masaya
Vice Project Leader ,
Genome Medical Sciences Project ,
National Center for Global Health and Medicine
Research on development of predictive markers for COVID-19 prognosis To Be Announced
FY2020 TAKEUCHI
Ichiro
Professor,
Department of Medicine,
Yokohama City University
Patient Stratification for Optimizing Resource Distribution and Outcome To Be Announced
FY2020 YAMAYOSHI
Seiya
Project Associate Professor,
Institute of Medical Science,
University of Tokyo
Antibody response against SARS-CoV-2 infection and serosurveillance To Be Announced

(6) Basic Reasearch on Infectious Diseases including COVID-19

Research Period Principal Investigator Affiliation Project Title General Description
FY2018 MORISHIMA Tsuneo  VisitngProfessor,
Pediatrics,
Aichi Medical University
 
Research on the diagnosis and treatment of severe respiratory infections caused by viruses To Be Announced
FY2019 SUZUKI Tadaki Chief,
Department of Pathology,
National Institute of Infectious Diseases
Development of pathological diagnostic methods for congenital infections and unexplained illness of possible To Be Announced
FY2020 ARASE
Hisashi
Professor,
Research Institute for Microbial Disease,
Osaka University
Development of methods of prevention or treatment for severe pneumonia caused by SARS-CoV2 infection To Be Announced
FY2020 IWAMI
Shingo
Associate Professor,
Department of Biology,
Kyushu University
Platform development for finding optimal antiviral treatment based on non-specific virus infection dynamics To Be Announced
FY2020 KASAHARA
Yuuya
Sub-project Leader,
Center for Drug Design Research,
National Institutes of Biomedical Innovation, Health and
Nutrition
Development of artificial nucleic acid aptamer for diagnosis, prevention and treatment of COVID-19 To Be Announced
FY2020 SUZUKI
Koichi
Professor,
Faculty of Medical Technology,
Teikyo University
Development of rapid, point-of-care diagnostic tool applicable for emerging infectious diseases without a
need of specific device nor technique
To Be Announced
FY2020 TAOKA
Kazuki
Assistant Professo,
Department of hematology and oncology,
The University of Tokyo Hospital
Development of a triage system for the severity of COVID19 pneumonia using artificial intelligence To Be Announced
FY2020 HIRAI
Toyohiro
Professor,
Department of Respiratory Medicine,
Kyoto University
Research and development of cloud-based lesion quantification system for emerging and re-emerging infectious diseases such as COVID-19 using interstitial pneumonia quantification technology. To Be Announced
FY2020 FUJITANI
Shigeki
Professor,
Department of Emergency and Critical Care Medicine,
Department of Emergency and Critical Care Medicine
 
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) for COVID-19 response To Be Announced
FY2020 MATSUNAGA
Akihiro
Senior Scientist,
Department of Intractable Diseases,
National Center for Global Health and Medicine
Study of the screening of the donor patients for the plasma transfusion therapy by measuring the neutralization
antibody against COVID-19.
To Be Announced
FY2020 MINEGISHI
Naoko
Professor,
Tohoku Medical Megabank Organization,
 
Validation of anti-SARS-CoV2 antibody detection methods and application to the preventive
medicine, using the biospecimen and data stored in population- and hospital- based biobanks
To Be Announced

2020.3.4

Last updated 2021.6.2